Finally, we provide the first evidence of the dysregulation of hepatic HTR2A and HTR2B mRNA abundance in women with MO and NAFLD, which could suggest a new therapeutic target. The gene discussed is HTR2A; the disease is metabolic dysfunction-associated steatotic liver disease.